Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEWELL-302: Bezacitinib vs Best Available Therapy in Hydroxyurea-resistant/intolerant Polycythemia Vera
ChiCTR2600124544Phase 3Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bezacitinib in polycythemia vera (PV) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete hematologic remission and ≥35% reduction in spleen volume from baseline. Started May 2026; status: completed.
02
Drugs
bezacitinib
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on ChiCTR2600124544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124544.